Advanced search
Publication Cover
Annals of Medicine Volume 53, 2021 - Issue 1
Submit an article Journal homepage
3,663
Views
2
CrossRef citations to date
0
Altmetric
Infectious Diseases

A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection

Ying Lia Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China;b Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, ChinaView further author information
,
Yousheng Yinc Department of Nephrology, The Affiliated Hospital of Guilin Medical College, Guilin, ChinaView further author information
,
Xiaomei Pengd Department of Urology, People’s Hospital of Guangxi Autonomous Region, Nanning, ChinaView further author information
,
Hongguang Zhenge Department of Nephrology, General Hospital of Northern Theater Command, Shenyang, ChinaView further author information
,
Fajun Fuf Department of Urology, Changsha Central Hospital, Changsha, ChinaView further author information
,
Zhenxiang Liug Department of Urology, Haikou People’s Hospital, Haikou, ChinaView further author information
,
Xiongfei Wuh Department of Nephrology, The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing, ChinaView further author information
,
Xiaoyan Wui Department of Nephrology, Zhongnan Hospital, Wuhan University, Wuhan, ChinaView further author information
,
Song Zhengj Department of Urology, Union Hospital Affiliated to Fujian Medical University, Fuzhou, ChinaView further author information
,
Nan Chenk Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaView further author information
,
Leye Hel Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, ChinaView further author information
,
Laicheng Renm Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, ChinaView further author information
,
Zhaohui Nin Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaView further author information
,
Detian Lio Department of Nephrology, Shengjing Hospital, China Medical University, Shenyang, ChinaView further author information
,
Peiyu Liangp Department of Urology, The Affiliated Hospital of Hainan Medical University, Haikou, ChinaView further author information
,
Xiaoju Lvq Department of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, ChinaView further author information
&
Yingyuan Zhanga Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China;b Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 217-226 | Received 20 Oct 2020, Accepted 02 Dec 2020, Published online: 17 Dec 2020

References

  • Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2010;122(6):7–15.
  • Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med. 2001;135(1):41–50.
  • Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284.
  • Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US Health Care System. JAMA Intern Med. 2013;173(22):2039–2046.
  • Kang CI, Kim J, Park DW, et al. Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections . Infect Chemother. 2018;50(1):67–100.
  • Hsueh P-R, Hoban DJ, Carmeli Y, et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect. 2011;63(2):114–123.
  • Sitafloxacin insert package . Daiichi Sankyo Company, Limited (Tokyo, Japan); 2020.
  • Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc). 2008;44(7):489–501.
  • Tiengrim S, Phiboonbanakit D, Thunyaharn S, et al. Comparative in vitro activity of sitafloxacin against bacteria isolated form Thai patients with urinary tract infections and lower respiratory tract infections. J Med Assoc Thai. 2012;95:S6–S17.
  • Wu X, Fan Y, Zhang J, et al. Pharmacokinetic and pharmacokinetic/pharmacodynamic study on oral administration of sitafloxacin in healthy Chinese subjects. Chin J Infect Chemother. 2018;18:352–358.
  • Manosuthi W, Wiboonchutikul S. Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus. 2016;5:410.
  • Kawada Y, Ishihara S, Matsui T, et al. Comparative study on sitafloxacin and levofloxacin in complicated urinary tract infections. Jpn J Chemother. 2008;56:S81.
  • Shimoda K, Ikeda T, Okawara S, et al. Possible relationship between phototoxicity and photodegradation of sitafloxacin, a quinolone antibacterial agent, in the auricular skin of albino mice. Toxicol Sci. 2000;56(2):290–296.
  • Dawe RS, Ibbotson SH, Sanderson JB, et al. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol. 2003;149(6):1232–1241.
  • Kandil H, Cramp E, Vaghela T. Trends in antibiotic resistance in urologic practice. Eur Urol Focus. 2016;2(4):363–373.
  • Tirupathi R, Areti S, Salim SA, et al. Acute bacterial skin and soft tissue infections: new drugs in ID armamentarium. J Community Hosp Intern Med Perspect. 2019;9(4):310–313.
  • Chao YS, Farrah K. Fluoroquinolones for the treatment of urinary tract infection: a review of clinical effectiveness, cost-effectiveness, and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
  • Ocheretyaner ER, Park TE. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Expert Rev Anti Infect Ther. 2018;16(7):523–530.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.